Summary
18 / 100 · Bulios Score
What speaks for it
- Analysts expect revenue to grow by 151% this fiscal year.
What to watch
- The company made a loss over the last 12 months.
- Repaying its net debt would take 17.7 years of operating profit.
- It passes only 2 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedThe company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
Revenue (USD)
Diluted EPS (USD)
- Analyst estimate
For the next fiscal year analysts expect revenue to grow by 151%.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $1.93B.
Profitability in detailIs it financially healthy?
Debt is a burdenOver the last 12 months it spent more cash than it brought in. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 21
- Hold 9
- Sell 1
Today's price within the analysts' price targets
The average target of $143.05 is 134% above today's price. 68% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
The company reports no revenue by product.
By region
- UNITED STATES 94%
- Non-US 6.4%
UNITED STATES brings in 94% of revenue.
Segments in detail